BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Metropolis Healthcare Ltd.'s Q2 FY22 revenue grew by 5% YoY led by higher revenue contribution from non-Covid-19 business which grew 38% YoY.
Superb cost control led to in-line Ebitda of Rs 902 million. Lower tax rate led to 5% beat on profit after tax of Rs 583 million.
Home collection non-Covid-19 business grew by 17% YoY, and revenue from this business is expected to ramp up.
Metropolis Healthcare is on track to cover 100 locations in home visit business by end of FY22, which is currently at 89.
With organised players benefiting from higher traction in home collection and enhanced brand recognition, Metropolis Healthcare is expected to do well given its rapid expansion in new regions.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR